Detailed Narrative
Q4 & FY25 Financial Performance Overview
Medplus Health Services Limited reported consolidated revenue of INR15,096 million for Q4 FY25, achieving an operating EBITDA of INR803 million, which translates to a 5.3% margin. For the full fiscal year 2025, the company's consolidated revenue reached INR61,361 million, with an operating EBITDA of INR2,776 million, representing a 4.5% margin. Pharmacy operations were the primary revenue driver, contributing 99% of the total, and grew by 14.8% on a GMV basis and 8.6% on a net basis for FY25.
Strategic Store Expansion and Network Optimization
In FY25, MedPlus added a net total of 305 stores, including 113 new stores in Q4, expanding its network to 4,712 stores across 2.5 million square feet. The company has set an ambitious target of 600 net store additions for FY26. Management highlighted efficient store ramp-up, with 58% of stores opened between April-September 2024 achieving breakeven within 6 months, and all stores combined reaching breakeven in 5 months.
Private Label Growth and Margin Enhancement
Private label sales significantly contributed to the revenue mix, accounting for 23.3% of total revenue in Q4 FY25. The GMV share of private label pharma increased to 20.9% in the current quarter, up from 7.9% in Q1 FY24. The company projects pharmacy gross margins to improve to 24.5-24.75% going forward⏳, with consolidated gross margins expected to be in the 25.5-25.8% range, driven by a consistent 1% quarterly growth in private label share.
Backend Infrastructure and Supply Chain Strengthening
To support its expansion and improve efficiency, MedPlus added 10 additional warehouses in FY25. Management acknowledged that previous supply chain and manpower constraints, particularly in remote areas and due to high attrition in larger cities, had impacted sales growth and fill rates. The new warehouses are strategically located to densify state-level supply and enhance service delivery to remote parts, with only one currently fully functional and others ramping up.
Diagnostics Segment Turnaround and Expansion Plans
The Diagnostics segment demonstrated a strong turnaround, reporting INR280 million in revenue for Q4 FY25, an increase from INR232.4 million in Q4 FY24. Crucially, the segment achieved an operating EBITDA of INR34.3 million in Q4 FY25, reversing a loss of INR11.3 million in Q4 FY24. As of March 31, 2025, active plans stood at 157,000, covering 327,000 lives, with a target to reach 250,000 plans to facilitate expansion into new states.
Capital Allocation and Strategic Priorities for Next 3 Years
Management outlined three key priorities for the next three years: achieving the target of 600 net store additions, successfully implementing a franchisee store pilot to share investment burden and optimize people management, and continuing private label growth to further expand margins. While no immediate plans for promoter stake sale were disclosed, it was indicated that any future sale would primarily be aimed at clearing existing debt.
Future Growth Drivers and Product Pipeline
The company anticipates future revenue growth to primarily stem from same-store sales growth, projected to be in the high single digits to low double-digit range. New store additions, while significant, are not expected to be major top-line drivers initially. MedPlus is also strategically preparing for the launch of private label GLP-1 products by March 2026, acknowledging the need for cold chain management but viewing it as a manageable operational aspect.